Skip to main content
Explore URMC

menu

Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery

Research Question:
Does the drug neoadjuvant endocrine therapy when given in combination with the drug fulvestrant help to shrink breast cancer and stop it from growing?

Basic Study Information

Purpose:
The study is being conducted to determine whether neoadjuvant endocrine therapy with fulvestrant or the combination of anastrozole and fulvestrant, is better than anastrozole when given before surgery to shrink the cancer and stop it from growing. Anastrozole inhibits tumor growth by reducing the levels of estrogen and has been approved by the Food and Drug Administration (FDA) of the United States for use after surgery for postmenopausal women with estrogen receptor positive breast cancer. It is also considered a standard of care to give anastrozole for a few months before surgery to shrink the tumor. Fulvestrant inhibits tumor cell growth by reducing the levels of estrogen receptor in the tumor cell. It is not approved by the FDA for use in women with early stage breast cancer before or after surgery, but is approved by the FDA for patients with advanced (Stage 4) estrogen receptor positive breast cancer that has spread to other parts of the body.

Location: University of Rochester Medical Center
Study Reference #: CBRS14062

Lead Researcher (Principal Investigator)

Lead Researcher: Kristin Skinner

Study Contact Information

Study Coordinator: Kathryn Corcoran
Phone: (585) 275-7771
Email: Kathryn_Corcoran@URMC.Rochester.edu

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search